Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Trial Title: Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

NCT ID: NCT06414733

Condition: Metastatic Breast Cancer
Metastatic Gastrointestinal Carcinoma
HER2-positive Breast Cancer
HER2-positive Gastric Cancer
EGFR Overexpression

Conditions: Official terms:
Breast Neoplasms

Conditions: Keywords:
Phase I
Breast Cancer
GI Cancer

Study type: Interventional

Study phase: Phase 1

Overall status: Not yet recruiting

Study design:

Allocation: Non-Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Biological
Intervention name: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720
Description: Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 720 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 720, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
Arm group label: HER-2 vaccine Breast
Arm group label: HER-2 vaccine GI

Summary: This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.

Criteria for eligibility:
Criteria:
Inclusion Criteria: Inclusion Criteria for Extension and Expansion Cohorts 1. For the extension cohort to be conducted at the IUSCCC (N=12), patients with histologically documented metastatic or unresectable breast or gastrointestinal cancer will be enrolled. 2. For the expansion cohort (N=30), patients with either histologically documented metastatic or unresectable breast cancer (N=15), or histologically documented metastatic or unresectable gastrointestinal cancer (N=15) be enrolled. All patients enrolled to this cohort are required to have measurable disease. Note: Measurable disease is defined as ≥ 1 lesions that can be accurately measured in ≥ 1 dimensions as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan. Inclusion Criteria for all Cohorts: 3. Patients must have received or refused first line standard systemic therapy for their metastases (if applicable) and patients with histologically confirmed pancreatic and esophageal cancers must have received no more than two prior cytotoxic chemotherapy regimens in the last two years after standard therapy. Patients with histologically confirmed breast, and gastrointestinal cancers must have received no more than three prior cytotoxic chemotherapy regimens in the last two years after standard therapy. 4. Progressive disease after at least one line of standard therapy. 5. Patients with pancreatic and esophageal cancers must have received no more than two prior cytotoxic chemotherapy regimens in the last two years. Patients with breast and gastrointestinal cancers must have received no more than three prior cytotoxic chemotherapy regimens in the last two years. 6. Patients are required to have HER-2 (IHC 1+, 2+ and 3+) or EGFR over-expression (FISH and IHC) to be enrolled on this study. 1. If the patient has had HER-2 expression measured prior to enrollment, the report alone will be accepted on the expansion phase of the study. 2. If the patient has had EGFR expression measured prior to enrollment, the report alone will be accepted on the dose escalation phase of the study. 3. If the patient has not had HER-2 or EGFR expression measured prior to enrollment on this study, it would be obligatory for the patient to have the tests performed to justify their status. HER-2 status can be performed by a variety of tests. Either IHC or FISH assay are acceptable if breast tumor tissues (previously frozen) are available. The test can be done at OSU or elsewhere if the patient is from out of town. 7. Patients with prior history of treated brain metastases who are off steroids and have stable metastatic brain disease for at least 3 months are eligible. 8. Patients must be ambulatory with an ECOG performance status 0, 1, or 2 (appendix II). 9. Patients must have adequate organ function as defined by: 1. ANC ≥ 1,000/mm³, platelet count > 100,000/mm³. 2. Serum bilirubin < 1.5 mg%, regardless of whether patients have liver involvement secondary to tumor. ALT must be < 2 times upper limit of normal. 3. Creatinine <1.5 mg/dl or calculated creatinine clearance > 60 ml/min 10. Patients must be at least 3 weeks past any prior surgery, cytotoxic, chemotherapy, other immunotherapy, hormonal therapy, or radiation therapy. Patients having been treated with monoclonal antibodies may enter the trial after a specified period of time (2 times the mean half life of the agent). Patients must have recovered from any toxicity of prior therapy prior to enrolling on study except for neuropathy where patients need to recover to less than grade 2. 1. Patients with hormone receptor positive breast cancer who are on stable endocrine therapy are eligible if their tumor has some expression of HER-2 based on IHC of 1+ or 2+. 11. Patients must be at least 18 years of age. 12. Women of child-bearing potential must not be pregnant and must have a negative pregnancy test (Women of childbearing potential definition: (ECOG definition)). 13. Men and women must agree to practice effective contraception while on this study. 14. Patients must obtain a base line Echocardiogram or MUGA and require the left ventricular ejection fraction to be within normal limits (or 50% or higher). 15. Ability to understand and the willingness to sign a written informed consent document. The patient must be aware that his/her disease is neoplastic in nature and willingly consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts. Exclusion Criteria: 1. Patients with tumors that are negative for HER-2 expression based on IHC of 0 AND Fluorescence in-situ hybridization showing lack of HER-2 amplification based on most recent ASCO/CAP guidelines; or are under-expressing EGFR based on FISH and IHC. 2. Patients on targeted therapies, such as Cycline Dependent Kinase (CDK) 4/6 or mammalian target of rapamycin (mTOR) inhibitors in combination with endocrine therapy 3. Patients who are {MVF-HER-2(266-296) and MVF-HER-2 (597-626)} immediate hypersensitivity skin test positive. 4. Patients who have evidence of active infection that requires antibiotic therapy. Patients must have been off antibiotic treatment for at least 3 weeks prior to initiating treatment and must be confirmed to be clear of the infection. 5. Patients with known active HIV, hepatitis A, hepatitis B, or hepatitis C infection. 6. Patients with serious uncontrolled cardiopulmonary disorders, including congestive heart failure, symptomatic coronary artery disease, serious cardiac arrhythmia, and symptomatic chronic obstructive pulmonary disease or patients with other serious uncontrolled medical diseases. At the discretion of the treating physician, patients who show disease control for at least 6 months may be enrolled. 7. Patients who require or likely to require corticosteroids or other immunosuppressives for intercurrent disease are NOT eligible. 8. Splenectomized patients. 9. Patients with active autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis dermato-myositis, or a vasculitic syndrome. Note: At the discretion of the treating physician, patients who show disease control for at least 6 months may be enrolled. 10. Patients who have developed anaphylactic responses to other vaccines

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Indiana University Melvin & Bren Simon Comprehensive Cancer Center

Address:
City: Indianapolis
Zip: 46202
Country: United States

Contact:
Last name: Xin Bryan, RN

Phone: 317-274-5495
Email: zhongx@iu.edu

Investigator:
Last name: Kathy Miller, MD
Email: Principal Investigator

Start date: November 1, 2024

Completion date: June 2027

Lead sponsor:
Agency: Pravin T.P Kaumaya
Agency class: Other

Source: Indiana University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06414733